Abstract SD-3-1
New Therapies for Diabetes and Protection of Diabetic Kidney Disease Beyond Blood Glucose Hirofumi Makino Okayama University Hospital, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
The most problematic issue in clinical nephrology is relentless and progressive increase in the patients with end-stage renal disease (ESRD) in worldwide. Among various kidney diseases, the impact of diabetic nephropathy on the increasing population with chronic kidney disease (CKD) and ESRD is enormous. Diabetic nephropathy is characterized by accumulation of extracellular matrix in glomeruli, called exudative, diffuse and nodular lesions. They are finally followed by glomerulosclerosis and interstitial fibrosis, and in such situation, the patients inevitably undergo dialysis therapies and renal transplantation to survive. We have been emphasizing the importance of chronic inflammation and oxidative stress in the progression of diabetic nephropathy and the identification of key molecules would facilitate to the development of new therapeutic strategies. We focused and emphasized on the anti-inflammatory and anti-oxidative effects of glucagon-like peptide-1 (GLP-1) receptor agonist and dipeptidyl peptidaSE-4 (DPP4) inhibitors, which ameliorated the progression of diabetic nephropathy in rodent models. We also recently investigated the beneficial role of sodium glucose cotransporter-2 (SGLT2) inhibitors on the progression of diabetic nephropathy using various animal models and reported SGLT2 inhibitors primarily ameliorates oxidative stress and inflammation in proximal tubular cells. New therapies such as incretin-related drugs and SGLT2 inhibitors would have the additional benefit in the protection of diabetic nephropathy beyond blood glucose control.
113
